Development of Sm-153 chitosan for radiosynovectomy

@inproceedings{Samaneh2010DevelopmentOS,
  title={Development of Sm-153 chitosan for radiosynovectomy},
  author={Zolghadri Jahromi Samaneh and Jalilian Amir Reza and Yousefnia Pasha Hassan and Bahrami Samani Ali and Shirvani Arani Simindokht and Mazidi Ali Mohammad and Ghannadi Maragheh Mohammad},
  year={2010}
}
Introduction: Developing new radiosynovectomy agents is of great importance due to the aging of human populations around the world and increasing the incidence of inflammatory diseases. In this work, Sm-153 chitosan agent was developed for the first time in our country and preparation and quality control of the compound is described. Methods: Sm-153 chloride was obtained by thermal neutron flux (4-5 × 10 n.cm.s) of natural Sm2O3 sample, dissolved in acidic media. Sm-samarium chloride (370 MBq… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 10 REFERENCES

Lanthanides as anticancer agents.

  • Current medicinal chemistry. Anti-cancer agents
  • 2005
VIEW 1 EXCERPT

Biological and clinical aspects of Lanthanide coordination compounds

SN Misra, MA Gagnani, M ID, RS. Shukla
  • Bioinorg Chem Appl
  • 2004
VIEW 1 EXCERPT

Biodistribution and kinetics of holmium-166-chitosan complex (DW-166HC) in rats and mice.

  • Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • 1998
VIEW 1 EXCERPT

Correction of arthritic deformities in the lower extremities and spine, arthritis and allied conditions, 9 edition

C. B. Sledge
  • Philadelphia: Lea and Febiger;
  • 1979
VIEW 1 EXCERPT

Similar Papers

Loading similar papers…